Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SCYX
- Price
- 0.73
- Stock movement down
- -0.01 (-0.70%)
- Company name
- Scynexis Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 34.14M
- Ent value
- 45.92M
- Price/Sales
- 3.99
- Price/Book
- 0.58
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 1.45
- PEG
- -
- EPS growth
- -
- 1 year return
- -52.93%
- 3 year return
- -34.44%
- 5 year return
- -34.53%
- 10 year return
- -36.82%
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SCYX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.99 |
| Price to Book | 0.58 |
| EV to Sales | 5.36 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.92M |
| EPS (TTM) | -0.75 |
| FCF per share (TTM) | -0.45 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.57M |
| Gross profit (TTM) | -6.25M |
| Operating income (TTM) | -52.13M |
| Net income (TTM) | -36.44M |
| EPS (TTM) | -0.75 |
| EPS (1y forward) | 0.55 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -72.93% |
| Operating margin (TTM) | -608.57% |
| Profit margin (TTM) | -425.41% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 28.73M |
| Net receivables | 9.66M |
| Total current assets | 80.46M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 99.04M |
| Accounts payable | 4.96M |
| Short/Current long term debt | 15.90M |
| Total current liabilities | 25.72M |
| Total liabilities | 40.51M |
| Shareholder's equity | 58.53M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.84M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -21.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -62.26% |
| Return on Assets | -36.80% |
| Return on Invested Capital | -50.51% |
| Cash Return on Invested Capital | -30.27% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.81 |
| Daily high | 0.83 |
| Daily low | 0.80 |
| Daily Volume | 43K |
| All-time high | 145.00 |
| 1y analyst estimate | 4.67 |
| Beta | 1.64 |
| EPS (TTM) | -0.75 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| SCYX | S&P500 | |
| Current price drop from All-time high | -99.44% | -1.46% |
| Highest price drop | -99.53% | -56.47% |
| Date of highest drop | 30 Jun 2025 | 9 Mar 2009 |
| Avg drop from high | -83.56% | -10.99% |
| Avg time to new high | 236 days | 12 days |
| Max time to new high | 2660 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
34.14M
Marketcap category
Small-cap
Description
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Employees
28
Website
Investor relations
-
SEC filings
CEO
Marco Taglietti
Country
USA
City
Jersey City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page